Characteristics | No. | ||
---|---|---|---|
Discontinuation of regorafenib | 21 | ||
 | Reason for discontinuation (includes duplication) |  | |
 |  Progression of primary disease | 14 | |
 |  Hepatic dysfunction | 3 | |
 |  Hypertension | 2 | |
 |  Nephropathy/proteinuria | 2 | |
 |  High fever | 2 | |
 |  Erythema multiforme | 2 | |
 |  Diarrhea | 1 | |
Interruption of regorafenib | 22 | ||
 | Reasons for interruption (includes duplication) |  | |
 |  Hepatic dysfunction | 9 | |
 |  Hypertension | 6 | |
 |  High fever | 6 | |
 |  Nephropathy/proteinuria | 4 | |
 | HFSR | 3 | |
 |  Erythema multiforme | 2 | |
 |  Thrombocytopenia | 2 | |
 |  Diarrhea | 1 | |
 |  Fatigue | 1 | |
 |  Nosebleed | 1 | |
Dose reduction of regorafenib | 4 | ||
 | Reasons for dose reduction (includes duplication) |  | |
 |  High fever | 2 | |
 |  Hypertension | 2 | |
 |  Nephropathy/proteinuria | 1 | |
 |  Thrombocytopenia | 1 | |
 |  Fatigue | 1 |